Citations 0
Editor's Correspondence
November 23, 2009

Optimal Anticoagulation Therapy in Patients With Valvular Heart Disease or Atrial Fibrillation

Author Affiliations

Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009

Arch Intern Med. 2009;169(21):2032-2033. doi:10.1001/archinternmed.2009.420

The recent study by Torn et al1 provides an interesting and insightful prospective analysis of the optimal anticoagulant strategy using vitamin K antagonists. The incidence of major thromboembolic events in 3 patient groups (mechanical heart valves, AF, and myocardial infarction) was analyzed and compared with the incidence of major hemorrhage. As a result of this study, the authors suggest that perhaps a target INR of 3.0 should be used for AF and mechanical heart valves, while an INR of 3.5 should be achieved in those patients who have sustained a myocardial infarction. The nature of the outcome events, however, may be important in modifying these conclusions.

First Page Preview View Large
First page PDF preview
First page PDF preview